Clinical trial
Natriuretic-ureothelic Adaptation of Body Fluid Homeostasis During SGLT-2 Inhibition and/or Mineralocorticoid Receptor Modulation in Patients With Chronic Kidney Disease. A 4-arm, Double-blind, Double-dummy, Parallel-group, Phase 2 Study to Investigate the Mechanistic Effects of Dapagliflozin, Dapagliflozin + Balcinrenone, Balcinrenone and Placebo on Body Solute and Water Homeostasis and Energy Metabolism in Male and Female Participants Over 50 Years of Age With Chronic Kidney Disease.
NCT05884866 is registered in ClinicalTrials.gov with Klinikum Nürnberg as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Natriuretic-ureothelic Adaptation of Body Fluid Homeostasis During SGLT-2 Inhibition and/or Mineralocorticoid Receptor Modulation in Patients With Chronic Kidney Disease. A 4-arm, Double-blind, Double-dummy, Parallel-group, Phase 2 Study to Investigate the Mechanistic Effects of Dapagliflozin, Dapagliflozin + Balcinrenone, Balcinrenone and Placebo on Body Solute and Water Homeostasis and Energy Metabolism in Male and Female Participants Over 50 Years of Age With Chronic Kidney Disease.
- Lead sponsor
- Klinikum Nürnberg
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- July 13, 2023
- Completion date
- January 28, 2026
- Enrollment
- 103 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
chronic kidney disease stage 3, chronic renal failure, electrolyte and fluid balance conditions, mechanistic effects of sglt2 inhibition and/ or mr antagonism on body fluid and electrolyte homeostatis